Loading…

Loading grant details…

Active OTHER RESEARCH-RELATED NIH (US)

Transspinal Magnetic Stimulation for the Treatment of Neuropathic Pain

$35.66M USD

Funder NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
Recipient Organization Massachusetts General Hospital
Country United States
Start Date Sep 18, 2024
End Date Aug 31, 2027
Duration 1,077 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 11037147
Grant Description

ABSTRACT. Chronic pain ranks among the top reasons for seeking medical attention. Spinal Cord Stimulation (SCS) has been a traditional approach for managing chronic neuropathic pain in the back and legs. This method, however, involves an invasive procedure that requires the patient to live with an implant. In contrast, Low-Intensity Focused

Ultrasound (LIFU) presents a non-invasive alternative explored in clinical trials for modifying central nervous system activity, promising quicker neuromodulation for pain relief. Our research shows that a brief, three-minute LIFU treatment targeting the dorsal root ganglion (DRG) can suppress pain responses in small and large animal

models for extended periods. Yet, targeting other crucial spinal areas for pain management, like the dorsal columns, remains a challenge due to anatomical constraints. Building on the development of an advanced miniaturized Transcranial Stimulation (TMS) system, our project aims to create a groundbreaking High Frequency (HF) Trans-Spinal Magnetic Stimulation (TSMS) tool. This new

system draws upon previous successes in dorsal column stimulation research and numerical simulations, setting the stage for the first non-invasive dorsal spinal cord stimulation to address back pain. Utilizing a novel 10kHz magnetic pulse, the HF-TSMS system mirrors the frequency used in invasive SCS treatments, which have been

effective in managing sciatica and significantly reducing opioid use among patients. We aim to refine HF-TSMS to target neural pathways involved in neuropathic back and leg pain. To achieve this, we plan to conduct experimental studies using rodent models at Massachusetts General Hospital, assessing

pain responses via fMRI. Further efficacy and safety evaluations will be conducted in larger animal models at the University of Arizona. Following these studies, we aim to secure an Investigational Device Exemption (IDE) and initiate a preclinical pilot trial in humans suffering from neuropathic pain. The introduction of HF-TSMS as a

non-invasive, drug-free treatment option could significantly impact the management of chronic neuropathic pain, offering new hope for patients with sciatica.

All Grantees

Massachusetts General Hospital

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant